Prävention und Management kardiovaskulärer Erkrankungen mit Nilotinib

• Verfasst von: Kiani, Alexander [VerfasserIn]
• Verfasst von: Saußele, Susanne [VerfasserIn]
• Titel: Prävention und Management kardiovaskulärer Erkrankungen mit Nilotinib
• Titelzusatz: Empfehlungen einer interdisziplinären Expertengruppe
• Paralleltitel: Prevention and management of cardiovascular diseases during treatment with the tyrosine kinase inhibitor nilotinib
• Paralleltitelzusatz: recommendations of an interdisciplinary expert group
• Verf.angabe: A. Kiani, P. Kuhlencordt, A. Hochhaus, H. Tesch, S. Saussele, P. Le Coutre
• E-Jahr: 2015
• Jahr: August 2015
• Umfang: 8 S.
• Fussnoten: Gesehen am 30.01.2017
• Titel Quelle: Enthalten in: Der Onkologe
• Ort Quelle: Berlin : Springer, 1996
• Jahr Quelle: 2015
• Band/Heft Quelle: 21(2015), 8, Seite 724-731
• ISSN Quelle: 1433-0415
• DOI: doi:10.1007/s00761-015-2990-5
• Datenträger: Online-Ressource
• Sprache: ger eng
• Sach-SW: Cardiovascular event
• Sach-SW: Cardiovascular risk
• Sach-SW: Kardiovaskuläres Ereignis
• Sach-SW: Kardiovaskuläres Risiko
• Sach-SW: Langzeittoxizitäten
• Sach-SW: Long-term side effects
• Sach-SW: Oncology
• Sach-SW: Peripheral arterial occlusive disease
• Sach-SW: Periphere arterielle Verschlusskrankheit
• Sach-SW: Tyrosine kinase inhibitor
• Sach-SW: Tyrosinkinaseinhibitor
• K10plus-PPN: 1552519821

Abstract

Background Due to the increasing use of targeted substances for the treatment of cancer diseases, hematologists and oncologists are increasingly confronted with unexpected side effects. Severe long-term side effects are of special importance for patients with a good prognosis and require an interdisciplinary approach. One example is the tyrosine kinase inhibitor nilotinib, which represents an important treatment option for patients with chronic myeloid leukemia. Generally, nilotinib is well tolerated but recent reports have suggested that nilotinib is associated with an increased cardiovascular risk. Methods This article presents the recommendations of an interdisciplinary expert group of hematologists and vascular specialists with respect to the prevention and treatment of cardiovascular diseases during treatment of patients with nilotinib. Results and conclusion Prior to the initiation of treatment all patients should be stratified with respect to their individual cardiovascular risk. Patients of the highest risk category should preferably be treated with an alternative tyrosine kinase inhibitor, if comparable treatment options are available. During treatment with nilotinib all patients should be regularly monitored, with the content and frequency of the monitoring tailored to the individual cardiovascular risk. Cardiovascular risk factors should be meticulously treated and special attention should be paid to early signs of progressive atherosclerosis. An algorithm is suggested for the management of patients with signs of progressive atherosclerosis or occurrence of a cardiovascular event during treatment with nilotinib.